The stock of TransCode Therapeutics Inc (RNAZ) has seen a 4.58% increase in the past week, with a -20.44% drop in the past month, and a -28.19% decrease in the past quarter. The volatility ratio for the week is 12.12%, and the volatility levels for the past 30 days are at 9.44% for RNAZ. The simple moving average for the last 20 days is -10.95% for RNAZ stock, with a simple moving average of -97.76% for the last 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
The 36-month beta value for RNAZ is at -0.24. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 6.54M, and currently, shorts hold a 0.28% of that float. The average trading volume for RNAZ on April 26, 2024 was 574.62K shares.
RNAZ) stock’s latest price update
TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has increased by 19.35 compared to its previous closing price of 0.44. However, the company has seen a 4.58% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-06 that BOSTON, March 06, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
RNAZ Trading at -18.92% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.85% of loss for the given period.
Volatility was left at 9.44%, however, over the last 30 days, the volatility rate increased by 12.12%, as shares sank -23.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.70% lower at present.
During the last 5 trading sessions, RNAZ rose by +3.59%, which changed the moving average for the period of 200-days by -99.49% in comparison to the 20-day moving average, which settled at $0.5816. In addition, TransCode Therapeutics Inc saw -92.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAZ starting from Dudley Robert Michael, who purchase 98,000 shares at the price of $0.51 back on Sep 28 ’23. After this action, Dudley Robert Michael now owns 180,262 shares of TransCode Therapeutics Inc, valued at $49,980 using the latest closing price.
Fitzgerald Thomas A, the Chief Financial Officer of TransCode Therapeutics Inc, purchase 49,350 shares at $0.51 during a trade that took place back on Sep 28 ’23, which means that Fitzgerald Thomas A is holding 56,318 shares at $25,168 based on the most recent closing price.
Stock Fundamentals for RNAZ
The total capital return value is set at -11.56. Equity return is now at value -759.85, with -290.74 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -40.11. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 686.65.
Currently, EBITDA for the company is -18.9 million with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
In conclusion, TransCode Therapeutics Inc (RNAZ) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
